Caris Life Sciences (CAI) FCF Margin (2024 - 2026)

Caris Life Sciences' FCF Margin history runs 3 years deep, the most recent figure standing at 15.28% for Q1 2026.

• On a quarterly basis, FCF Margin rose 4117.0% year-over-year to 15.28% in Q1 2026; TTM through Mar 2026 was 16.26%, a 4803.0% increase from a year earlier, with the FY2025 full-year figure at 10.25%, up 7177.0% from the prior year.
• FCF Margin declined to 15.28% in Q1 2026 per CAI's latest filing, from 19.12% in the prior quarter.
• Across five years, FCF Margin topped out at 25.52% in Q3 2025 and bottomed at 64.22% in Q3 2024.
• The 3-year median for FCF Margin is 1.75% (2025), against an average of 9.25%.
• Across the five-year window, FCF Margin surged 8974 bps in 2025 and soared 4117 bps in 2026, its largest moves.
• Year by year, FCF Margin stood at 36.34% in 2024, then surged by 153 bps to 19.12% in 2025, then retreated by 20 bps to 15.28% in 2026.
• Per Business Quant, the three latest CAI FCF Margin figures stand at 15.28% (Q1 2026), 19.12% (Q4 2025), and 25.52% (Q3 2025).